Previous Article | Next Article 
Molecular and Cellular Biology, December 2000, p. 8740-8747, Vol. 20, No. 23
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Combinatorial Effect of T-Cell Receptor Ligation
and CD45 Isoform Expression on the Signaling Contribution of the
Small GTPases Ras and Rap1
Jan
Czyzyk,1,2
David
Leitenberg,1,3
Tom
Taylor,1 and
Kim
Bottomly1,*
Section of
Immunobiology,1 Department of
Pathology,2 and Department of Laboratory
Medicine,3 Yale University School of
Medicine, New Haven, Connecticut 06510
Received 21 March 2000/Returned for modification 24 April
2000/Accepted 8 September 2000
 |
ABSTRACT |
By using ligands with various affinities for the T-cell receptor
(TCR) and by altering the contribution of the CD45 tyrosine phosphatase, the effects of the potency of TCR-induced signals on the
function of small GTPases Ras and Rap1 were studied. T cells expressing
low-molecular-weight CD45 isoforms (e.g., CD45RO) exhibited the
strongest activation of the Ras-dependent Elk-1 transcription factor
and the highest sensitivity to the inhibitory action of dominant
negative mutant Ras compared to T cells expressing high-molecular-weight CD45 isoforms (ABC). Moreover, stimulation of
CD45RO+, but not CD45ABC+, T cells with a
high-affinity TCR ligand induced suboptimal Elk-1 activation compared
with the stimulation induced by an intermediate-affinity TCR-ligand
interaction. This observation suggested that the Ras-dependent signaling pathway is safeguarded in CD45RO+ expressors by a
negative regulatory mechanism(s) which prohibits maximal activation of
the Ras-dependent signaling events following high-avidity TCR-ligand
engagement. Interestingly, the biochemical activity of another small
GTPase, the Ras-like protein Rap1, which has been implicated in the
functional suppression of Ras signaling, was inversely correlated with
the extent of Elk-1 activation induced by different-affinity TCR
ligands. Consistently, overexpression of putative Rap dominant negative
mutant RapN17 or the physiologic inhibitor of Rap1, the Rap
GTPase-activating protein RapGAP, augmented the Elk-1 response in
CD45RO+ T cells. This is in contrast to the suppressive
effect of RapN17 and RapGAP on CD45ABC+ T cells,
underscoring the possibility that Rap1 can act as either a repressor or
a potentiator of Ras effector signals, depending on CD45 isoform
expression. These observations suggest that cells expressing distinct
isoforms of CD45 employ different signal transduction schemes to
optimize Ras-mediated signal transduction in activated T lymphocytes.
 |
INTRODUCTION |
The affinity of interaction between
antigen and T-cell receptor (TCR) is essential in determining the level
of TCR phosphorylation (17) and other early signaling
parameters (4, 44). Such differential regulation of TCR
signaling has important biological consequences during the immune
response, including early T-cell maturation (13), peripheral
Th1-Th2 helper subset differentiation (21), and memory
T-cell generation (28). Furthermore, signaling output from
the TCR is tightly regulated by a constitutively highly expressed CD45
membrane protein tyrosine phosphatase (19, 20). Whereas the
role of the cytoplasmic domain of CD45 is thought to regulate the
activities of tyrosine kinases Lck (31) and Fyn
(29), the function of the heavily glycosylated CD45
ectodomain is not well established. Complexity of this domain is
introduced by alternative splicing of four exons encoding the
O-glycosylated N-terminal sequence of the CD45 ectodomain and
generation of several isoforms with molecular masses of 170, 180, 190, 205, and 220 kDa (47). Although the heterogeneity of the
CD45 ectodomain is correlated with different stages of T-cell
activation, differentiation, and maturation (9, 34) and
certain biochemical differences exist between T cells with differential
expression of CD45 isoforms (27, 33, 39), the precise
function of individual CD45 isoforms during acquisition of different
functional profiles remains poorly understood.
Similarly, despite the knowledge that the character of the antigen
binding by the TCR complex is a key factor influencing different
cellular outcomes of the immune response, the mechanisms by which
individual signaling pathways from the TCR contribute to the
development of different cellular functions are not clear. Of interest
in this regard are studies indicating that a classic Ras-induced
signaling pathway influences the processes of thymocyte development
(1, 45), cytokine gene expression (2, 32, 36),
and Th2 helper cell differentiation (50), suggesting that
Ras proteins provide an important signaling intermediate necessary for
coupling of the TCR to distinct cellular phenotypes.
p21Ras and p21Rap1 are members of the Ras
protein family which are prominently activated from the stimulated TCR
by distinct but similarly organized signaling cascades (3, 10, 24,
37). These two closely related small GTPases share absolute
identity within the core effector domain and can bind a similar
spectrum of target molecules (6). However, the functional
consequences of these interactions appear to be different, depending on
whether Ras or Rap1 is involved. It has been proposed that because Rap1 is located in the endoplasmic reticulum and Golgi, it may sequester Ras
effectors in a subcellular location that prevents their complete activation, thereby suppressing Ras effector signaling. Consistent with
this model is the observation that Rap1 antagonizes the effects of
oncogenic Ras (18). Also, it has been suggested that the cause of T-cell anergy lies in a block in the
Ras-Raf-1-mitogen-activated protein (MAP) kinase cascade (11,
25) and that inhibition of this pathway in functionally
unresponsive T cells correlates with active, GTP-bound Rap1 complexed
with Raf-1 (3). These considerations raise the possibility
that Ras and Rap1 maintain a close functional relationship which may
effectively integrate and modify signal transduction events induced by
the TCR.
Work from our laboratory (30) and by others (27)
revealed that T cells carrying distinct isoforms of CD45 produce
significantly different amounts of interleukin-2 (IL-2). Our motivation
to analyze the role of Ras during this differential response was
spurred by several reports demonstrating that Ras is critical for IL-2 transcription (2, 32, 36) and that the expression of CD45 has been correlated with distinct abilities of T cells to activate Ras
(33). In this study, we simulated conditions which are
required in primary T lymphocytes for the induction of different
cellular outcomes by using differential TCR ligation and selective CD45 display. Under these conditions, we analyzed Ras and Rap1 signaling and
potential cross talk between the pathways and linked the expression of
single CD45 isoforms to distinct response patterns in T cells.
 |
MATERIALS AND METHODS |
Antibodies.
Anticlonotypic D10 TCR monoclonal antibodies
(MAbs) 3D3 (immunoglobulin G1 [IgG1]) and 5A (IgG1) were used for
stimulation (42). The antibodies were purified from culture
supernatants on protein G columns and dialyzed against
phosphate-buffered saline (PBS) before use. Fluorescein
isothiocyanate-labeled 30-F11 (panspecific anti-mouse CD45, rat IgG2b)
and phyroerythrin-labeled MAbs 16A (anti-mouse CD45RB, rat IgG2a),
GK1.4 (anti-mouse CD4, rat IgG2b), and H57-597 (anti-mouse TCR
-chain, hamster IgG) were used to phenotype BW clones in flow
cytometry analysis. MAb 30-F11 was also used in a Western blot analysis
to verify the proper molecular weight of CD45 isoforms in individual BW
clones (see Fig. 1C). All labeled MAbs were purchased from PharMingen.
Anti-Rap1/Krev-1 rabbit polyclonal IgG was from Santa Cruz Biotech.
Cell culture and activation.
A CD45-negative variant of the
AKR thymoma BW5147 reconstituted with the TCR from the D10.G4.1 (D10)
Th2 cell clone, wild-type murine CD4, and single CD45 isoforms (ABC,
RO, or Exon-1) has been described previously (30). BW cells
were maintained in Eagle's high-amino-acid medium supplemented with
10% fetal calf serum, 2 mM L-glutamine, 10 mM HEPES, and
antibiotics. Neomycin, puromycin, and hygromycin were added to maintain
stable expression of the D10 TCR, CD4, and CD45, respectively. BW
T-cell clones that express similar levels of CD45, CD4 coreceptor, and
the D10 TCR were sorted and routinely immunophenotyped by
immunofluorescence to ensure similar expression of these molecules.
Stimulations were performed in 96-well flat-bottom microtiter plates
precoated for 4 h with different dilutions of anticlonotypic TCR
MAb 3D3 or 5A. BW cells (105) were added to each well and
stimulated for 24 h. For stimulation with the antigen-presenting
cells, 5 × 105 BW cells were cocultured with 2.5 × 106 mitomycin C-treated B10BR
(H-2k) T-cell depleted splenocytes and the CA37
conalbumin peptide (100 µg/ml) and incubated for 48 h. Following
stimulation, BW cells were harvested and analyzed for reporter gene expression.
Expression plasmids and reporter systems.
Cells were
transfected by the standard DEAE-dextran method with the following
constructs. pCGN-Raf-N4 encodes residues 23 to 284 of c-Raf-1 and was
donated by C. J. Der (University of North Carolina at Chapel
Hill). The dominant negative construct pcDNA3-RasN17 was a gift from K. L. Guan (University of Michigan). pZIPneoSV(X)1-RapN17, Rap63E, and
RapGAP were kindly provided by L. A. Quilliam (Indiana
University). The dominant negative mutant forms of Erk-1 and Erk-2 were
gifts from M. H. Cobb (University of Texas).
The PathDetect trans-reporting system (Stratagene) consists of the
plasmid that expresses a chimeric fusion consisting of the GAL4 DNA
binding domain fused to the activation domain of Elk-1 and the reporter
vector that contains luciferase downstream of a basic promoter element
(TATA box) which is joined to five tandem repeats of the 17-bp GAL4
binding element. The chimeric IL-2-Luc reporter construct contains the
luciferase gene under the control of the immediate upstream region
(positions
7 to
293) of a mouse IL-2 gene and was provided by C. Dong (Yale University) with permission from E. Serfling (University of
Würzburg) (43). The pRL-CMV plasmid containing the
Renilla luciferase gene under the control of the
cytomegalovirus immediate-early enhancer-promoter region and the
dual-luciferase reporter assay system were purchased from Promega and
used for normalization of the experimental firefly luciferase gene expression.
The pB4X-CAT reporter plasmid contains the bacterial gene for
chloramphenicol acetyltransferase (CAT) driven by a minimal
promoter
that contains four tandem copies of the Ets/AP-1 Ras-responsive
element
from the polyomavirus enhancer (
5). At 48 h
posttransfection,
cells were collected, washed with PBS, resuspended in
0.25 M Tris
(pH 7.8), and lysed by three cycles of freezing-thawing.
Portions
of the cleared cell lysates were incubated with acetyl
coenzyme
A and [
14C]chloramphenicol (DuPont, Boston,
Mass.) for 45 min at 37°C.
Following extraction in ethyl acetate,
samples were dried under
vacuum, resuspended in ethyl acetate, and
chromatographed on silica
gel 1B thin-layer chromatography plates
(Baker, Phillipsburg,
N.J.) in chloroform-methanol (95/5 ratio).
Radioactivity in each
spot was measured by the Molecular Imager System
GS-525 (Bio-Rad
Laboratories) and analyzed by the Molecular
Analyst/Macintosh
data analysis software. The amount of acetylated
[
14C]chloramphenicol was calculated as a percentage of
the total
[
14C]chloramphenicol.
Rap1 activation assay.
Rap1 activity was measured by means
of an activation-specific probe assay as previously described
(12). Briefly, 5 × 106 rested BW cells
were stimulated with plate-bound MAb 5A or 3D3 for 30 min, washed once
with ice-cold PBS, and lysed in 1% NP-40-50 mM Tris (pH 7.4)-150 mM
NaCl. Lysates were clarified by centrifugation, and supernatants were
incubated with 5 µg of glutathione S-transferase (GST)
bound to the 97-amino-acid sequence spanning the Rap1 binding domain of
RalGDS precoupled to glutathione-agarose beads. After 1 h at
4°C, the beads were washed four times with lysis buffer and the
materials collected were analyzed by sodium dodecyl sulfate-12% polyacrylamide gel electrophoresis, followed by transfer to a nitrocellulose membrane which was blocked for 1 h and probed with an anti-Rap1 polyclonal antibody.
Special reagents.
The conalbumin peptide CA37
(HRGAIEWEGIESG) was synthesized by the W. M. Keck Foundation
Biotechnology Resource Laboratory and purified by high-pressure liquid
chromatography prior to use. Phorbol myristate acetate (PMA; Sigma) was
used at 50 ng/ml. PD98059 is a MEK1 inhibitor and was obtained from New
England Biolabs Inc.
Western immunoblotting for CD45.
BW cells (107)
cultured in normal media were lysed in buffer containing 1% NP-40-20
mM Tris (pH 7.5)-150 mM NaCl-1 mM MgCl2-1 mM
EGTA-leupeptin at 10 µg/ml-1 mM phenylmethylsulfonyl fluoride-1 mM
sodium vanadate. Equal amounts of protein from precleared cell lysates
were fractioned under nonreducing conditions on a sodium dodecyl
sulfate-6% polyacrylamide gel. After electrophoresis, proteins were
electroblotted onto nitrocellulose membranes (Bio-Rad Laboratories),
blocked with 5% nonfat dry milk, probed for 1 h with
biotin-conjugated MAb 30-F11, and then incubated with avidin-coupled horseradish peroxidase. The immunoblots were developed with the ECL
chemiluminescence detection system (Amersham Pharmacia Biotech).
 |
RESULTS |
Expression of low-molecular-weight isoform of CD45 increases
transactivation from Ras-dependent molecular reporter constructs.
To study the effects of distinct CD45 isoforms on lymphocyte function,
our laboratory has developed a system in which CD45-negative mutant
murine thymoma BW5147 T cells were reconstituted with single isoforms
of CD45. Using the BW transfectants, it was demonstrated that clones
with the lowest-molecular-weight (RO) isoforms of CD45 produce
significantly more IL-2 following antigen stimulation compared with the
high-molecular-weight (ABC) CD45 expressors (23, 30) and
that this preferential cytokine response was strongly correlated with
the increased physical interaction of CD45RO isoforms with the TCR-CD4
complex (22, 23). We now wished to understand the
mechanism(s) that couples differential organization of the TCR-CD4-CD45
interacting complex to different IL-2 cytokine outcomes. In this
regard, we have concentrated our efforts on the Ras-MAP kinase cascade,
a signaling pathway which has been repeatedly implicated in the
regulation of the IL-2 response (2, 32, 36). However, since
activation of the IL-2 gene is a complex process depending on input
from various signaling pathways, we have used Ras-dependent plasmid
reporter constructs rather than full-length or minimal-length IL-2
promoter constructs. We hoped that in this way we could separate the
effects of CD45 isoforms on Ras-MAP kinase signaling from the effects
that these CD45 isoforms exhibit toward other signaling processes. In
the first system, the activity of a chimeric GAL4-Elk-1 reporter
containing the Ras-dependent C-terminal domain of Elk-1 fused to the
DNA binding domain of GAL4 was tested. In this experiment, TCR-induced transcriptional activity of GAL4-Elk-1 was potently inhibited by
RafN4, Mek inhibitor PD098059, and interfering forms of Erks (extracellular signal-regulated kinases) (Fig.
1D). These data indicate that TCR
stimulation activates Elk-1 via the Ras-Erk signaling pathway. A
CD45-negative control cell clone did not activate Elk-1 via the TCR,
despite the ability of these cells to respond to serum (Fig. 1E).
Subsequently, all of the CD45ABC+ and CD45RO+
clones were transfected with the reporter stimulated with anti-TCR clonotypic MAb 5A. As shown in Fig. 1A, CD45RO expressors demonstrated the strongest relative transactivation upon treatment with the antibody, suggesting that Ras is most efficiently activated via the TCR
in these cells.

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 1.
Preferential activation of the Ras-MAP kinase signaling
cascade in CD45RO+ T cells (part 1). (A)
CD45ABC+ and CD45RO+ TCR+
CD3+ CD4+ BW5147 T-cell clones, in the order
indicated in panel C, were transfected with an Elk-1-GAL4
transactivator and a 5×GAL4-luciferase reporter at a ratio of 1:10 and
stimulated for 24 h with plate-bound anti-D10 TCR MAb 5A (10 µg/ml). The relative activity of the reporter is expressed as fold
induction over reporter transactivation in unstimulated cells. (B)
CD45ABC+ and CD45RO+ cells were transfected
with the Elk-1-GAL4-5×GAL4-luciferase reporter, cotransfected with
50 ng of RasN17 or a matched empty vector, and stimulated with MAb 5A.
Luciferase activities were normalized against an internal control
(pRL-CMV). (C) Western blot analysis of whole-cell lysates of
CD45ABC+ (clones 17.11, 17.4, and 23.3) and
CD45RO+ (clones 19.9 and 18.16) cells stained with
anti-CD45 MAb 30-F11. (D) CD3+ CD4+
CD45RO+ BW5147 cells were transfected with Elk-1-GAL4 (or
the GAL4 DNA binding domain [GAL4dbd] alone) and a 5×GAL4-luciferase
reporter and cotransfected with either the empty vector (Emp. vec.) or
an expression plasmid(s) containing the dominant negative mutant forms
of Erk or Raf (RafN4) under the control of a constitutive promoter. At
24 h posttransfection, cells were left unstimulated or were
stimulated for another 24 h with an anti-TCR MAb. Luciferase
activity (in relative luciferase units [RLU]) was normalized against
the protein concentration of the cell lysates and expressed as a
percentage of the control stimulation. DMSO, dimethyl sulfoxide. (E)
Transactivation of the Elk-1-GAL4-5×GAL4-luciferase reporter system
in CD45-positive and CD45-negative BW cells upon stimulation with an
anti-TCR MAb (top) or 20% fetal calf serum (FCS) following overnight
starvation (bottom). The data shown are representative of at least two
independent experiments.
|
|
Similar data were obtained with a second construct which contains four
ets-Ap-1 promoter elements from the polyomavirus enhancer
and can be transactivated by the cytoplasmic oncogenes that encode
v-Ras and v-Raf (
5). First, we confirmed that the Ras-Raf-1
cascade elicits similar responses from pB4X-CAT during TCR stimulation
of the BW cells used in these studies, since both the dominant
negative
Raf mutant (RafN4) and PD098059 strongly inhibited reporter
activity
following stimulation of cells with the antigen (Fig.
2B). Importantly, CD45RO expressors, upon
stimulation with the
peptide-pulsed antigen-presenting cells,
transactivated the CAT
reporter much better than CD45ABC
+
cells, again suggesting that Ras is more efficiently upregulated
via
the TCR in cells carrying low-molecular-weight CD45 isoforms
(Fig.
2A).

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 2.
Preferential activation of the Ras-Raf-Mek signaling
cascade in CD45RO+ T cells (part 2). Transactivation of the
reporter construct pB4X-CAT in CD45-negative (CD45NEG),
CD45ABC+ (clones 17.11, 17.4, and 23.3), and
CD45RO+ (clones 19.9 and 18.16) TCR+
CD3+ CD4+ BW5147 T cells. Cells in the
indicated order were transfected with the CAT reporter and stimulated
for 48 h with the antigen (Ag; conalbumin peptide CA37 [100
µg/ml] or PMA [50 ng/ml]). The relative activity of the reporter
is expressed as the ratio of stimulation with the peptide to
stimulation with PMA. (B) Autoradiogram of thin-layer chromatography
and conversion of acetylated [14C]chloramphenicol in a
CAT assay of TCR+ CD3+ CD4+
CD45+ T cells transiently transfected with pB4X-CAT alone
(control, dimethyl sulfoxide [DMSO], and PD98059) or transfected with
pB4X-CAT and cotransfected with either an empty vector control (pCGN)
or an expression plasmid containing dominant negative mutant Raf
(RafN4). Posttransfection, cells were nonstimulated, stimulated for
48 h with CA37 without additional treatment, or stimulated and
simultaneously treated with dimethyl sulfoxide or 10 µM Mek1
inhibitor PD98058. APCs, antigen-presenting cells.
|
|
Next, we measured the sensitivity of TCR-induced
CD45ABC
+ and CD45RO
+ BW cells to the
dominant negative mutant form of Ras. Interestingly,
CD45RO
+ clones, which in previous experiments showed the
highest relative
reporter transactivation, here also were the most
efficiently
inhibited by RasN17 (Fig.
1B). These two observations
together
strongly suggest that the preferential transactivation of the
Ras-responsive promoters in CD45RO
+ cells is due to the
greater proportional contribution of Ras
during TCR-induced responses
in these cells. Importantly, the
data obtained using luciferase and CAT
assays are consistent with
previous work done in this laboratory
showing that BW thymoma
RO but not ABC CD45 expressors are good IL-2
producers. The Ras-MAP
kinase pathway may therefore, at least in part,
be responsible
for the phenomenon of this preferential cytokine
responsiveness.
CD45RO expression prohibits maximal T-cell activation following
stimulation with high-affinity TCR ligands.
BW transfectants are
advantageous because, in addition to CD45, they express the CD4
accessory molecule, as well as the CD3 complex and the functional TCR
derived from the D10 Th2 cell clone (30). A panel of MAbs
was previously raised against this TCR and characterized extensively
with respect to the epitopes recognized in the D10 TCR, as well as
affinity for the D10 TCR (40, 42). Importantly, some of
these D10 TCR-specific antibodies potently recruit CD4 upon TCR
binding, thereby mimicking physiologic stimulation of T cells with the
antigen-myosin heavy chain complex. Since the relative affinity of
ligands is known in this system, mutant BW cells bearing the D10 TCR
are ideal for experiments aimed at determining differential effects of
high- and low-affinity ligand-TCR interactions on signal transduction
events. Interestingly, the above-described increased activation of the
Ras signaling pathway in a CD45RO+ BW clone (Fig. 1A) was
observed in the context of stimulation with anti-D10 TCR clonotypic MAb
5A but not 3D3. Hence, we wondered whether MAb 5A- and 3D3-induced
changes in D10 TCR+ CD4+ BW T cells are
differentially regulated by distinct CD45 isoforms. Dose-response
experiments were conducted in which maximal activation of Elk-1 was
compared in cells stimulated with MAbs 5A and 3D3. These experiments
revealed significantly higher transactivation of Elk-1 upon treatment
of CD45RO+ cells with MAb 5A, as opposed to the stimulation
of these cells with MAb 3D3 (Fig. 3A).
Since MAb 3D3 exhibits higher affinity for the D10 TCR than does MAb 5A
(51), as well as greater potency as defined by the ability
to cocap CD4 with the TCR (40), it was unexpected to find
more prominent absolute Elk-1 activation in BW cells treated with MAb
5A. We also investigated the generality of this phenomenon by testing
other BW clones carrying single isoforms of CD45. From these
experiments, it became clear that the MAb 5A-induced augmentation of
Elk-1 transactivation, compared to that induced by MAb 3D3, was seen
primarily in CD45RO+ cells but not in CD45ABC+
cells (Fig. 3C).

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 3.
Intermediate- but not high-avidity TCR-CD4 ligands
induce maximal Elk-1 transactivation and IL-2 responses in
CD45RO+ T cells. CD45ABC+ and
CD45RO+ BW cells were transfected with the
Elk-1-GAL4-5×GAL4-luciferase construct (A and C) or with the
IL-2-luciferase construct (B and D). At 24 h posttransfection,
105-cell aliquots were incubated in 96-well plates
precoated with MAb 3D3 or 5A. After stimulation, cells were collected
and lysed and the luciferase activity was measured and normalized
against the protein concentration. (A and B) Transcriptional functional
assay monitoring activity of Elk-1 (A) or the IL-2 minimal promoter (B)
in CD45RO+ 19.9 cells stimulated with increasing
concentrations of anti-TCR clonotypic MAb 3D3 (open) or 5A (closed).
(C) Comparison of maximal Elk-1 activations during stimulation with
MAbs 3D3 (3D3max) and 5A (5Amax) in three
independent CD45ABC+ clones (17.11, 17.4, and 23.3) clones,
two CD45RO+ clones, (19.9 and 18.16), and one CD45 Exon-1
BW clone. (D) Similar analysis of the maximal responses from the IL-2
promoter conducted with one representative CD45ABC+ clone
and one CD45RO+ clone. The data in panel D are the ratios
between the maximal responses obtained with the two antibodies for each
cell clone. The data shown are representative of two to five
independent experiments. Ab, antibody.
|
|
Next, we studied whether MAb 5A-induced potentiation of T-cell
activation leads to enhanced activation of cytokine genes.
We therefore
transiently transfected BW cells with the IL-2-luciferase
reporter
construct and monitored its transactivation following
TCR ligation.
Again, in CD45RO
+ but not in CD45ABC
+ cells,
MAb 5A-induced stimulation caused a twofold stronger response
from the
IL-2 reporter over analogous treatment with MAb 3D3 (Fig.
3B and
D).
Since the activities of anti-D10 TCR clonotypic MAbs are believed to
involve a physical association of CD4 with the TCR (
40,
42),
we decided to next determine whether CD4 expression contributes
to the
MAb 5A-induced increase in Elk-1 activation. To answer
this question,
TCR
+ CD45RO
+ CD4-negative BW cells were sorted
(Fig.
4B) and compared to CD4-positive
counterparts in the Elk-1 transcriptional assay. In these experiments,
CD4-negative cells, like CD4-positive cells, were more strongly
stimulated with MAb 5A than with MAb 3D3. However, this effect
appeared
to be weaker compared with that in CD4
+ derivatives (Fig.
4A). Together, these data suggest that both
CD4-dependent and
CD4-independent mechanisms operate in the process
of inhibition of the
Ras-MAP kinase signaling pathway in CD45RO
+ cells following
stimulation of these cells with the high-affinity
TCR ligand.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 4.
Augmentation of Elk transactivation by the
intermediate-affinity TCR ligand is partially dependent on CD4. (A)
CD4+ or CD4 BW5147 TCR+
CD3+ CD45RO+ cells (clone 18.16) were
transfected with the Elk-1-GAL4-5×GAL4-luciferase reporter system
and the pRL-CMV internal vector control and stimulated with different
concentrations of plate-bound MAb 3D3 or 5A. Luciferase activity was
normalized against the internal reporter, and the ratio between the
maximal responses obtained with the two MAbs from each cell type was
determined. Numbers 1, 2, 3, and 4 indicate separate experiments. (B)
Flow cytometric analysis of CD45RO+ CD4+
(solid) and CD45RO+ CD4 (dots) BW cells
stained with phycoerythrin-labeled anti-CD4 MAb GK1.5. The cell surface
expression of CD45 and the TCR-CD3 complex was also measured and was
the same in both cell types (data not shown).
|
|
Rap1 mediates negative signaling in CD45RO+ T cells
stimulated with the high-affinity TCR ligand.
One possible
explanation of the finding that strong stimulation of the TCR-CD4
complex results in suboptimal transcriptional activation could be that
under this condition a negative regulatory mechanism is activated to
prohibit full triggering of Ras-MAP kinase pathway activation. Since
Rap1 has been implicated in the suppression of Ras-mediated effector
signaling in T cells (3), we deemed it important to compare
the levels of activated Rap1 in BW cells treated with MAbs 5A and 3D3.
Pulldown experiments employing the GST-Rap1 binding domain of RalGDS as
a probe for the active form of Rap1 (12) showed that
stimulation of CD45RO+ BW cells with MAb 5A induces less
accumulation of Rap1-GTP than does similar treatment with MAb 3D3 (Fig.
5A, left). In contrast, no such reduction
was seen in BW cells expressing CD45ABC (Fig. 5A, right). This
observation supports the view that the MAb 5A-dependent increase in
Elk-1 activation can be attributed to the reduced intracellular
concentration of Rap-GTP and diminished negative signaling in
CD45RO+ cells.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 5.
Rap1 suppresses T-cell stimulation in
CD45RO+ cells stimulated with high-affinity anti-TCR
ligand. (A) Pulldown experiments assessing Rap1 activity
(12). Equal numbers of TCR+ CD4+
CD45RO+ (left) or TCR+ CD4+
CD45ABC+ (right) BW5147 cells were unstimulated or treated
with plate-bound MAb 3D3 or 5A, lysed, and incubated with the GST-Rap
binding domain of RalGDS precoupled to glutathione-Sepharose 4B. The
washed, pulled down materials (top) or total lysates (bottom) were run
on the gel and stained with an anti-Rap1 antibody. IP,
immunoprecipitate; CN, unstimulated control; WB, Western blotting. (B)
Effect of dominant negative mutant RapN17 on
Elk-1-GAL4-5×GAL4-luciferase transactivation in CD45RO+
cells stimulated with different-affinity TCR ligands.
CD45RO+ BW thymona cells were transiently transfected with
the Elk-1 reporter and the pRL-CMV internal control and cotransfected
with either the empty vector control or the expression plasmid encoding
RapN17. Cells were than stimulated with different concentrations of MAb
3D3 (left) or 5A (right), and the effect of the mutant was determined
for each antibody concentration as the ratio of stimulation in cells
transfected with RapN17 to the stimulation in cells transfected with
the empty vector. Luciferase activities were normalized to the pRL-CMV
internal control. Similar results were obtained in three independent
experiments. (C) Effect of constitutively active mutant Rap63E on
Elk-1-GAL4-5×GAL4-luciferase in BW cells stimulated via the TCR.
TCR+ CD4+ CD45RO+ cells (clone
18.16) were transfected with the reporter, the internal control
(pRL-CMV), and 0.5 µg of the Rap63E expression plasmid (right) or the
empty vector (left) and stimulated with MAb 3D3. Luciferase activities
were normalized and expressed as fold induction over the reporter
transactivation in unstimulated cells. Vec. Con., vector control.
|
|
Next, utilizing the putative dominant negative mutant form of Rap1, we
reexamined the function of this small GTPase. Transient
expression of
RapN17 augmented by severalfold the activation of
the Elk-1 reporter
during stimulation with MAb 3D3 (Fig.
5B, left;
see also Fig.
6B,
left), mimicking previously seen effects of
the treatment of
CD45RO
+ BW cells with MAb 5A (Fig.
3A). Treatment of
CD45RO
+ cells with MAb 3D3 plus RapN17 produced a similar
or higher absolute
transactivation level of the Elk-1-luciferase
reporter than the
parallel MAb 5A-induced stimulation of the control
cells transfected
with the empty vector. Moreover, this prominent
potentiation by
RapN17 was particularly strong during stimulation with
high antibody
concentrations, suggesting that the negative function of
Rap1
is accentuated with increasing TCR-ligand interaction engagement
(Fig.
5B, left). Interestingly, stimulation of the TCR with MAb
5A was
less sensitive to this enhancing effect of mutant Rap1
(Fig.
5B,
right). In a control experiment with constitutively
active Rap63E, we
found that this mutant protein potently suppressed
TCR-induced Elk-1 in
CD45RO
+ cells (Fig.
5C). Together, the biochemical and
functional studies
strongly implicate Rap1 as an inhibitor of the Ras
signaling pathway
in T cells which carry the low-molecular-weight CD45
isoform and
whose TCR is highly engaged by the
ligand.
Transcriptional activation of Elk-1 requires involvement of
distinct members of the Ras protein family in CD45RO+ and
CD45ABC+ cells.
Rap1 appears to negatively influence
the activation of CD45RO+ T cells. We next wished to
determine the primary function of Rap1 in T lymphocytes expressing the
high-molecular-weight CD45 isoforms. To answer this question and better
understand the regulation of Ras proteins in T cells, experiments were
performed with the dominant negative mutant forms of Ras and Rap and
the physiologic Rap1 inhibitor RapGAP (41).
CD45RO+ and CD45ABC+ T cells were transiently
transfected with the Elk-1-GAL4-5×GAL4-luciferase constructs and
cotransfected with increasing doses of RasN17, RapN17, or RapGAP. As
before (Fig. 1B), the inhibitory capacity of RasN17 prevailed in
CD45RO+ cells (Fig. 6A left),
and this finding is consistent with earlier data showing that
Ras-dependent elements are better transactivated in CD45RO+
T cells (Fig. 1A and 2A). In contrast, RapN17 (Fig. 6B, left, and D)
and RapGAP (Fig. 6B, middle) significantly increased Elk-1 transactivation in CD45RO+ T cells. This was acutely
distinct from an inhibitory effect of these constructs on the Elk-1
reporter in CD45ABC+ expressors. This differential ability
of transdominant negative RasN17, and RapGAP or RapN17, to inhibit
TCR-induced activation of Ras proteins in cells expressing CD45RO or
CD45ABC suggests the possibility that distinct CD45 isoforms influence
TCR coupling to downstream signaling events via different Ras proteins.
In addition, because RapN17 and RapGAP augmented or suppressed Elk-1 transactivation in CD45RO+ and CD45ABC+ cells,
respectively, an argument can be made that Rap1 is activated in
CD45ABC+, as well as in CD45RO+, cells.
However, its primary function toward the MAP kinase signaling pathway
is distinctly determined by these different CD45 isoforms.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 6.
Differential requirements for Ras and Rap1 in
transactivation of Elk-1 in CD45ABC+ and
CD45RO+ T cells. CD45ABC+ (open) and
CD45RO+ (closed) BW cells were transfected with the
Elk-1-GAL4-5×GAL4 reporter; cotransfected with 0, 62.5, 125, 250, 500, or 1,000 ng of dominant negative mutant RasN17 (A) or RafN4 (C),
with 125, 250, 500, or 1,000 ng of RapGAP (B middle), or with 125, 250, 500, 1,000, or 2,000 ng of RapN17 (B, left and right); and stimulated
with an anti-TCR MAb (A, B, and C, left; B, middle) or PMA (A, B, and
C, right). The amount of total DNA used for each transfection was
adjusted with the matched empty vector control to 1.0 or 2.0 µg, as
required. (D) Comparison of the effects of RapN17 on
CD45ABC+ and CD45RO+ cells stimulated with
different concentrations of MAb 3D3. Cells were transfected with the
Elk-1-GAL4-4×GAL4-luciferase reporter and cotransfected with a
single dose of RapN17 or the empty vector control and stimulated with
different concentrations of MAb 3D3. The data are expressed as the
ratio of the stimulation in cell transfected with RapN17 to the
stimulation in cells transfected with the empty vector control.
Luciferase activities were normalized against the internal control
(pRL-CMV). RLU, relative luciferase units.
|
|
Several controls were included in this set of experiments. In the first
one, employing treatment of cells with phorbol ester,
activation of the
Elk-1 reporter was only mildly inhibited by
mutant RasN17 and with no
essential difference between CD45ABC
+ and
CD45RO
+ cells (Fig.
6A, right). This observation is
consistent with the
fact that PMA inhibits Ras GTPase-activating
protein (
10) and
increases the level of Ras-GTP
independently of the nucleotide
exchange factor activities affected by
the mutant RasN17 used
in this experiment. Also in the second control
experiment, no
major difference in the effects of RapN17 on PMA-induced
Elk-1
activation was seen between CD45RO
+ and
CDABC
+ cells (Fig.
6B, right). In the third control, mutant
RafN4, which
binds to the Ras and Rap1 effector domains, was able to
inhibit
TCR-induced transactivation of Elk-1 in both cell types with
similar
degrees of efficiency (Fig.
6C, left). This finding suggests
that
the differential effects of distinct CD45 isoforms on the MAP
kinase signaling pathway involve primarily proximal signal transduction
events which control distinct small G proteins and that these
differences merge at the level of the effector signals positioned
downstream of Ras and Rap1. Finally, in contrast to mutant RasN17,
RafN4 also inhibited the PMA-induced responses from the Elk-1
reporter
(Fig.
6C, right). This result is in agreement with the
notion that
PMA-induced active GTP-bound Ras requires a free effector
domain in
order to exercise its biological function on Elk-1.
 |
DISCUSSION |
The aim of this study was to define the role of different-size
isoforms of CD45 in the regulation of small-GTPase-mediated signaling
in T lymphocytes. Three observations emerged from our work. First, we
provided evidence that the expression of small CD45 isoforms (p170 and
p180) improves the ability of T cells to activate the Ras-MAP kinase
signaling pathway. In this regard, we showed that two distinct
Ras-regulated reporter systems are preferentially transactivated in T
cells expressing CD45RO and in addition that these strong responses are
highly sensitive to RasN17. Although it is unclear why
CD45RO+ cells preferentially transactivate Ras-dependent
signals rather than CD45ABC+ expressors, previous work in
this laboratory demonstrated that low- rather than
high-molecular-weight isoforms of CD45 interact with the TCR-CD3
complex (22, 23), suggesting an early mechanism by which the
extracellular portion of CD45 may regulate the extent of proximal
signaling events. According to this model, close interaction between
the TCR and CD45RO tyrosine phosphatase may cause higher activity of
the TCR-recruited proximal protein tyrosine kinases, leading to more
efficient recruitment of the adapter proteins and exchange factor Sos,
and ultimately result in improved Ras activation. Since Ras signaling
has been implicated in the upregulation of cytokine genes (2, 32,
36), such augmented function of Ras and its effectors in
activated CD45RO+ memory T cells might facilitate synthesis
and/or secretion of the effector cytokines in these cells.
Second, we have demonstrated that in CD45RO+ cells, the
clonotypic MAb (3D3) with high affinity for the TCR and high CD4
cocapping potency produced a suboptimal transcriptional outcome of the
Ras-MAP kinase pathway and that Rap1 activation is likely responsible for the negative regulation of Ras-induced effector signals during this
stimulation. One interpretation of this finding is that strong stimulation of the TCR complex, together with expression of
low-molecular-weight CD45 isoforms, may actually be harmful rather than
beneficial in obtaining maximal transcriptional responses. It is
possible that not only positive but also inhibitory signals operate at a higher rate in CD45RO+ than in CD45ABC+
cells. Such negative regulation of the Ras-MAP kinase pathway in
primary T lymphocytes may be important in the prevention of uncontrolled and cytokine-independent cell proliferation, it may protect T cells from overstimulation and antigen-induced death, or
alternatively, through downregulation of the antiapoptotic Ras effector
signals (15), it might decrease the survival potential of
activated CD45RO+ memory T cells.
Finally, experiments with the dominant negative mutant form of Rap1
suggested that, in contrast to CD45RO+ cells in which
p21Ras appears to be a major inducer of MAP kinase-Elk-1
responses, in CD45ABC+ cells this role is also played by
p21Rap1. We therefore propose that in T cells, Rap1 does
not act as a pure functional antagonist of Ras but rather that under
certain conditions it can also mimic Ras effects. This conclusion is
consistent with information available in the literature. Signaling
pathways consisting of Cbl and Crk adapter proteins and the C3G
exchange factor upregulate Rap1 in anergic T cells and implicate Rap1
in these cells in the suppression of Ras effector signals
(3). However, it has also been demonstrated that Rap1 can
cause positive effects independently of Ras while using similar or
identical Ras effector pathways (52). For example, in
neuronal PC12 cells, Rap has been connected with the cyclic AMP
(cAMP)-induced activation of B-Raf and subsequently the activation of
Mek and Erk and the transcription of Elk-1 (49). Thus, in
contrast to Ras, for which the predominant mechanism of activation is
association of guanine nucleotide exchange factors with the cell
membrane, Rap1 can be activated by highly motile second messengers. The
recently discovered protein Epac, an exchange protein activated by
cAMP, provides a potential mechanism by which cAMP may directly
activate Rap1 (8). Moreover, discoveries of other
Rap1-specific exchangers have revealed additional complexity of Rap1
regulation (7, 16). Although we do not fully understand the
proximal routes which couple TCR-CD45RO+ and
TCR-CD45ABC+ to distinct functions of Rap1, the existence
of multiple exchange factors for this small GTPase may provide an
effective way to polarize Rap1 functions in a single cell type.
It is noteworthy that in addition to Ras antagonistic and, under
certain circumstances, Ras synergistic effects on the MAP kinase
signaling pathway, Rap has also been indicated to have other unique
functions. Cell adhesion (14, 38, 48), cytoskeleton organization (46), and events controlling the mitochondrial oxidative burst (26, 35) are examples of the processes in which Rap is thought to be involved. In particular, two recent reports
have strongly implicated Rap as an important immunological modulator
during T-lymphocyte intercellular adhesion molecule and vascular
adhesion molecule binding (14, 38). Therefore, it is
plausible that in our studies examining the outcomes of Rap inhibition,
RapN17 and RapGAP do not necessarily work through the block of
influences on Raf kinases but rather might interfere with other
processes controlled by this small GTPase.
In conclusion, we propose that two factors, the size of the CD45
isoform expressed on the T-cell surface and the interaction affinity
between TCR-CD4 and antigen-major histocompatibility complex are
critical determinants of the signaling contributions of Ras and Rap1.
Accordingly, the stimulation of T cells with low-affinity ligands in
the presence of the high-molecular-weight isoform of CD45 results
primarily in functional synergism between Ras and Rap1. In contrast,
stimulation of T cells with high-affinity TCR ligands in the presence
of low-molecular-weight CD45 isoforms induces Rap activation, which
antagonizes Ras pathway signaling (Fig.
7). It will be interesting to know
whether the different functional relationships between Ras and Rap1
contribute to remote lymphocyte behaviors such as Th1-Th2 helper
differentiation, thymocyte maturation, or memory cell acquisition.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 7.
Model of the putative functional organization of Ras and
Rap1 by the TCR-CD4-CD45 interacting complex. Low-molecular-weight
isoforms of CD45 (RO) efficiently interact with the TCR, thereby
increasing the amplitude of the TCR effector signals. Under these
conditions, stimulation of the TCR-CD4 complex with the high-affinity
ligand (e.g., MAb 3D3) delivers a strong signal which involves Rap1
primarily in the negative regulation of Ras effector functions. In
contrast, stimulation of the TCR with intermediate-to-low-affinity
ligands (e.g., MAb 5A) fails to recruit CD4 and, in the presence of the
high-molecular-weight isoform of CD45 (ABC), generates a signal that is
below the threshold required for the negative regulation of Ras by Rap1
yet is sufficient to positively engage Rap1 toward the Ras-MAP kinase
signaling pathway.
|
|
 |
ACKNOWLEDGMENTS |
We thank C. A. Janeway and G. M. Losyev for MAbs 5A and 3D3,
C. J. Der for helpful suggestions and RafN4, L. A. Quilliam
for Rap constructs and RapGAP, Teresa Brtva and K. L. Guan for RasN17, M. H. Cobb for dominant negative Erk-1 and Erk-2, J. L. Bos for GST-RBD of RalGDS, and C. Dong and E. Serfling for the
IL-2-luciferase reporter construct. We also thank Teresa Brtva for
critical reading of the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Section of
Immunobiology, Yale University School of Medicine, 310 Cedar St.-LH
408, New Haven, CT 06510. Phone: (203) 785-5391. Fax: (203) 737-1764. E-mail: kim.bottomly{at}yale.edu.
 |
REFERENCES |
| 1.
|
Alberola-Ila, J.,
K. A. Forbush,
R. Seger,
E. G. Krebs, and R. M. Perlmutter.
1995.
Selective requirement for MAP kinase activation in thymocyte differentiation.
Nature
373:620-623[CrossRef][Medline].
|
| 2.
|
Baldari, C. T.,
G. Macchia, and J. L. Telford.
1992.
Interleukin-2 promoter activation in T-cells expressing activated Ha-ras.
J. Biol. Chem.
267:4289-4291[Abstract/Free Full Text].
|
| 3.
|
Boussiotis, V. A.,
G. J. Freeman,
A. Berezovskaya,
D. L. Barber, and L. M. Nadler.
1997.
Maintenance of human T cell anergy: blocking of IL-2 gene transcription by activated Rap1.
Science
278:124-128[Abstract/Free Full Text].
|
| 4.
|
Boutin, Y.,
D. Leitenberg,
X. Tao, and K. Bottomly.
1997.
Distinct biochemical signals characterize agonist- and altered peptide ligand-induced differentiation of naïve CD4+ T cells into Th1 and Th2 subsets.
J. Immunol.
159:5802-5809[Abstract].
|
| 5.
|
Bruder, J. T.,
G. Heidecker, and U. R. Rapp.
1992.
Serum-, TPA-, and Ras-induced expression from Ap-1/Ets-driven promoters requires Raf-1 kinase.
Genes Dev.
6:545-556[Abstract/Free Full Text].
|
| 6.
|
Campbell, S. L.,
R. Khosravi-Far,
K. L. Rossman,
G. J. Clark, and C. J. Der.
1998.
Increasing complexity of Ras signaling.
Oncogene
17:1395-1413[CrossRef][Medline].
|
| 7.
|
de Rooij, J.,
N. M. Boenink,
M. van Triest,
R. H. Cool,
A. Wittinghofer, and J. L. Bos.
1999.
PDZ-GEF1, a guanine nucleotide exchange factor specific for rap1 and rap2.
J. Biol. Chem.
274:38125-38130[Abstract/Free Full Text].
|
| 8.
|
de Rooij, J.,
F. J. Zwartkruis,
M. H. Verheijen,
R. H. Cool,
S. M. Nijman,
A. Wittinghofer, and J. L. Bos.
1998.
Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP.
Nature
396:474-477[CrossRef][Medline].
|
| 9.
|
Dianzani, U.,
M. Luqman,
J. Rojo,
J. Yagi,
J. L. Baron,
A. Woods,
C. A. Janeway, and K. Bottomly.
1990.
Molecular association on the T cell surface correlate with immunological memory.
Eur. J. Immunol.
20:2249-2257[Medline].
|
| 10.
|
Downward, J.,
J. D. Graves,
P. H. Warne,
S. Rayter, and D. A. Cantrell.
1990.
Stimulation of p21ras upon T-cell activation.
Nature
346:719-723[CrossRef][Medline].
|
| 11.
|
Fields, P. E.,
T. F. Gajewski, and F. W. Fitch.
1996.
Blocked Ras activation in anergic CD4+ T cells.
Science
271:1276-1278[Abstract].
|
| 12.
|
Franke, B.,
J. W. Akkerman, and J. L. Bos.
1997.
Rapid Ca2+-mediated activation of Rap1 in human platelets.
EMBO J.
16:252-259[CrossRef][Medline].
|
| 13.
|
Hogquist, K. A.,
S. C. Jameson,
W. R. Heath,
J. L. Howard,
M. J. Bevan, and F. R. Carbone.
1994.
T cell receptor antagonist peptides induce positive selection.
Cell
76:17-27[CrossRef][Medline].
|
| 14.
|
Katagari, K.,
M. Hattori,
N. Minato,
S.-K. Irie,
K. Takatsu, and T. Kinashi.
2000.
Rap1 is a potent activation signal for leukocyte function-associated antigen 1 distinct from protein kinase C and phosphatidylinositol-3-OH kinase.
Mol. Cell. Biol.
20:1956-1969[Abstract/Free Full Text].
|
| 15.
|
Kauffmann-Zeh, A.,
P. Rodriguez-Viciana,
E. Ulrich,
C. Gilbert,
P. Coffer,
J. Downward, and G. Evan.
1997.
Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB.
Nature
385:544-548[CrossRef][Medline].
|
| 16.
|
Kawasaki, H.,
G. M. Springett,
S. Toki,
J. J. Canales,
P. Harlan,
J. P. Blumenstiel,
E. J. Chen,
I. A. Bany,
N. Mochizuki,
A. Ashbacher,
M. Matsuda,
D. E. Housman, and A. M. Graybiel.
1998.
A Rap guanine nucleotide exchange factor enriched highly in the basal ganglia.
Proc. Natl. Acad. Sci. USA
95:13278-13283[Abstract/Free Full Text].
|
| 17.
|
Kersh, E. N.,
A. S. Shaw, and P. M. Allen.
1998.
Fidelity of T cell activation through multistep T cell receptor zeta phosphorylation.
Science
281:572-575[Abstract/Free Full Text].
|
| 18.
|
Kitayama, H.,
Y. Sugimoto,
T. Matsuzaki,
Y. Ikawa, and M. Noda.
1989.
A ras-related gene with transformation suppressor activity.
Cell
56:77-84[CrossRef][Medline].
|
| 19.
|
Koretzky, G. A.,
J. Picus,
T. Schultz, and A. Weiss.
1991.
Tyrosine phosphatase CD45 is required for T-cell antigen receptor and CD2-mediated activation of a protein tyrosine kinase and interleukin 2 production.
Proc. Natl. Acad. Sci. USA
88:2037-2041[Abstract/Free Full Text].
|
| 20.
|
Koretzky, G. A.,
J. Picus,
M. L. Thomas, and A. Weiss.
1990.
Tyrosine phosphatase CD45 is essential for coupling T-cell antigen receptor to the phosphatidyl inositol pathway.
Nature
346:66-68[CrossRef][Medline].
|
| 21.
|
Leitenberg, D., and K. Bottomly.
1999.
Regulation of naïve T cell differentiation by varying the potency of TCR signal transduction.
Sem. Immunol.
11:283-292[CrossRef][Medline].
|
| 22.
|
Leitenberg, D.,
Y. Boutin,
D. D. Lu, and K. Bottomly.
1999.
Biochemical association of CD45 with the T cell receptor complex: regulation by CD45 isoform and during T cell activation.
Immunity
10:701-711[CrossRef][Medline].
|
| 23.
|
Leitenberg, D.,
T. J. Novak,
D. Farber,
B. R. Smith, and K. Bottomly.
1996.
The extracellular domain of CD45 controls association with the CD4-T cell receptor complex and the response to antigen-specific stimulation.
J. Exp. Med.
183:249-259[Abstract/Free Full Text].
|
| 24.
|
Li, B.,
M. Subleski,
N. Fusaki,
T. Yamamoto,
T. Copeland,
G. L. Princler,
H. Kung, and T. Kamata.
1996.
Catalytic activity of the mouse guanine nucleotide exchanger mSOS is activated by Fyn tyrosine protein kinase and the T-cell antigen receptor in T cells.
Proc. Natl. Acad. Sci. USA
93:1001-1005[Abstract/Free Full Text].
|
| 25.
|
Li, W.,
C. D. Whaley,
A. Mondino, and D. L. Mueller.
1996.
Blocked signal transduction to the ERK and JNK protein kinases in anergic CD4+ T cells.
Science
271:1272-1276[Abstract].
|
| 26.
|
Maly, F.-E.,
L. A. Quilliam,
O. Dorseuil,
C. J. Der, and G. M. Bokoch.
1994.
Activated or dominant inhibitory mutants of Rap1A decrease the oxidative burst of Epstein-Barr virus-transformed human B lymphocytes.
J. Biol. Chem.
269:18743-18746[Abstract/Free Full Text].
|
| 27.
|
McKenney, D. W.,
H. Onodera,
L. Gorman,
T. Mimura, and D. M. J. Rothstein.
1995.
Distinct isoforms of the CD45 protein-tyrosine phosphatase differentially regulate interleukin 2 secretion and activation signal pathways involving Vav in T cells.
J. Biol. Chem.
270:24949-24954[Abstract/Free Full Text].
|
| 28.
|
Metz, D. P., and K. Bottomly.
1999.
Function and regulation of memory T cells.
Immunol. Res.
19:127-141[Medline].
|
| 29.
|
Mustelin, T.,
T. Pessa-Morikawa,
M. Autero,
M. Gassmann,
L. C. Andersson,
C. G. Gahmberg, and P. Burn.
1992.
Regulation of the p59fyn protein tyrosine kinase by the CD45 phosphotyrosine phosphatase.
Eur. J. Immunol.
22:1173-1178[Medline].
|
| 30.
|
Novak, T. J.,
D. Farber,
D. Leitenberg,
S. C. Hong,
P. Johnson, and K. Bottomly.
1994.
Isoforms of the transmembrane tyrosine phosphatase CD45 differentially affect T cell recognition.
Immunity
1:109-119[CrossRef][Medline].
|
| 31.
|
Ostergaard, H. L.,
D. A. Shackelford,
T. R. Hurley,
P. Johnson,
R. Hyman,
B. M. Sefton, and I. S. Trowbridge.
1989.
Expression of CD45 alters phosphorylation of the lck-encoded tyrosine protein kinase in murine lymphoma T-cell lines.
Proc. Natl. Acad. Sci. USA
86:8959-8963[Abstract/Free Full Text].
|
| 32.
|
Owaki, H.,
R. Vartma,
B. Gillis,
J. T. Bruder,
U. R. Rapp,
L. S. Davis, and T. D. Geppert.
1993.
Raf-1 is required for T cell IL2 production.
EMBO J.
12:4367-4373[Medline].
|
| 33.
|
Patel, H. R.,
H. Renz,
N. Terada, and E. W. Gelfand.
1994.
Differential activation of p21ras in CD45RA+ and CD45RO+ human T lymphocytes.
J. Immunol.
152:2830-2836[Abstract].
|
| 34.
|
Pilarski, L. M.,
R. Gillitzer,
H. Zola,
K. Shortman, and R. Scollay.
1989.
Definition of the thymic generative lineage by selective expression of high molecular weight isoforms of CD45 (T200).
Eur. J. Immunol.
19:589-597[Medline].
|
| 35.
|
Quinn, M. T.,
C. A. Parkos,
L. Walker,
S. H. Orkin,
M. C. Dinauer, and A. J. Jesaitis.
1989.
Association of a Ras-related protein with cytochrome b of human neutrophils.
Nature
342:198-200[CrossRef][Medline].
|
| 36.
|
Rayter, S. I.,
M. Woodrow,
S. C. Lucas,
D. A. Cantrell, and J. Downward.
1992.
p21ras mediates control of IL-2 gene promoter function in T cell activation.
EMBO J.
11:4549-4556[Medline].
|
| 37.
|
Reedquist, K. A., and J. L. Bos.
1998.
Costimulation through CD28 suppresses T cell receptor-dependent activation of the Ras-like small GTPase Rap1 in human T lymphocytes.
J. Biol. Chem.
273:4944-4949[Abstract/Free Full Text].
|
| 38.
|
Reedquist, K. A.,
E. Ross,
E. A. Koop,
R. M. F. Wolthuis,
F. J. T. Zwartkruis,
Y. van Kooyk,
M. Salmon,
C. D. Buckley, and J. L. Bos.
2000.
The small GTPase, Rap1, mediates CD31-induced integrin adhesion.
J. Cell Biol.
148:1151-1158[Abstract/Free Full Text].
|
| 39.
|
Robinson, A. T.,
N. Miller, and D. R. Alexander.
1993.
CD3 antigen-mediated calcium signals and protein kinase C activation are higher in CD45RO+ than in CD45RA+ human T lymphocyte subsets.
Eur. J. Immunol.
23:61-68[Medline].
|
| 40.
|
Rojo, J. M.,
K. Saizawa, and C. A. Janeway.
1989.
Physical association of CD4 and the T-cell receptor can be induced by anti-T-cell receptor antibodies.
Proc. Natl. Acad. Sci. USA
86:3311-3315[Abstract/Free Full Text].
|
| 41.
|
Rubinfeld, B.,
S. Munemitsu,
R. Clark,
L. Conroy,
K. Watt,
W. J. Crosier,
F. McCormick, and P. Polakis.
1991.
Molecular cloning of a GTPase activating protein specific for the Krev-1 protein p21rap1.
Cell
65:1033-1042[CrossRef][Medline].
|
| 42.
|
Saizawa, K.,
J. Rojo, and C. A. Janeway.
1987.
Evidence for a physical association of CD4 and CD3:alpha:beta T-cell receptor.
Nature
328:260-263[CrossRef][Medline].
|
| 43.
|
Serfling, E.,
R. Barthelmas,
I. Pfeuffer,
B. Schenk,
S. Zarius,
R. Swoboda,
F. Mercurio, and M. Karin.
1989.
Ubiquitous and lymphocyte-specific factors are involved in the induction of the mouse interleukin 2 gene in T lymphocyte.
EMBO J.
8:465-473[Medline].
|
| 44.
|
Sloan-Lancaster, J.,
A. S. Shaw,
J. B. Rothbard, and P. M. Allen.
1994.
Partial T cell signaling: altered phospho-zeta and lack of zap70 recruitment in APL-induced T cell anergy.
Cell
79:913-922[CrossRef][Medline].
|
| 45.
|
Swat, W.,
Y. Shinkai,
H. L. Cheng,
L. Davidson, and F. W. Alt.
1996.
Activated Ras signals differentiation and expansion of CD4+8+ thymocytes.
Proc. Natl. Acad. Sci. USA
93:4683-4687[Abstract/Free Full Text].
|
| 46.
|
Torti, M.,
A. Bertoni,
I. Canobbio,
F. Sinigaglia,
E. G. Lapetina, and C. Balduini.
1999.
Rap1B and Rap2B translocation to the cytoskeleton by von Willebrand factor involves Fc II receptor-mediated protein tyrosine phosphorylation.
J. Biol. Chem.
274:13690-13697[Abstract/Free Full Text].
|
| 47.
|
Trowbridge, I. S., and M. L. Thomas.
1994.
CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development.
Annu. Rev. Immunol.
12:85-116[CrossRef][Medline].
|
| 48.
|
Tsukamoto, N.,
M. Hattori,
H. Yang,
J. L. Bos, and N. Minato.
1999.
Rap1 GTPase-activating protein SPA-1 negatively regulates cell adhesion.
J. Biol. Chem.
274:18463-18469[Abstract/Free Full Text].
|
| 49.
|
Vossler, M. R.,
H. Yao,
R. D. York,
M. G. Pan,
C. S. Rim, and P. J. Stork.
1997.
cAMP activated MAP kinase and Elk-1 through a B-Raf and Rap1-dependent pathway.
Cell
89:73-82[CrossRef][Medline].
|
| 50.
|
Yamashita, M.,
M. Kimura,
M. Kuba,
C. Shimizu,
T. Tada,
R. M. Perlmutter, and T. Nakayama.
1999.
T cell antigen receptor-mediated activation of the Ras/mitogen-activated protein kinase pathway controls interleukin 4 receptor function and type-2 helper T cell differentiation.
Proc. Natl. Acad. Sci. USA
96:1024-1029[Abstract/Free Full Text].
|
| 51.
|
Yoon, S. T.,
U. Dianzani,
K. Bottomly, and C. A. Janeway.
1994.
Both high and low avidity antibodies to the T cell receptor can have agonist or antagonist activity.
Immunity
1:563-569[CrossRef][Medline].
|
| 52.
|
York, R. D.,
H. Yao,
T. Dillon,
C. L. Ellig,
S. P. Eckert,
E. W. McCleskey, and P. J. Stork.
1998.
Rap1 mediates sustained MAP kinase activation induced by nerve growth factor.
Nature
392:622-626[CrossRef][Medline].
|
Molecular and Cellular Biology, December 2000, p. 8740-8747, Vol. 20, No. 23
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Houston, E. G. Jr., Nechanitzky, R., Fink, P. J.
(2008). Cutting Edge: Contact with Secondary Lymphoid Organs Drives Postthymic T Cell Maturation. J. Immunol.
181: 5213-5217
[Abstract]
[Full Text]
-
Czyzyk, J., Chen, H.-C., Bottomly, K., Flavell, R. A.
(2008). p21 Ras/Impedes Mitogenic Signal Propagation Regulates Cytokine Production and Migration in CD4 T Cells. J. Biol. Chem.
283: 23004-23015
[Abstract]
[Full Text]
-
Stork, P. J. S., Dillon, T. J.
(2005). Multiple roles of Rap1 in hematopoietic cells: complementary versus antagonistic functions. Blood
106: 2952-2961
[Abstract]
[Full Text]
-
Remans, P. H. J., Gringhuis, S. I., van Laar, J. M., Sanders, M. E., Papendrecht-van der Voort, E. A. M., Zwartkruis, F. J. T., Levarht, E. W. N., Rosas, M., Coffer, P. J., Breedveld, F. C., Bos, J. L., Tak, P. P., Verweij, C. L., Reedquist, K. A.
(2004). Rap1 Signaling Is Required for Suppression of Ras-Generated Reactive Oxygen Species and Protection Against Oxidative Stress in T Lymphocytes. J. Immunol.
173: 920-931
[Abstract]
[Full Text]
-
Christian, S. L., Lee, R. L., McLeod, S. J., Burgess, A. E., Li, A. H. Y., Dang-Lawson, M., Lin, K. B. L., Gold, M. R.
(2003). Activation of the Rap GTPases in B Lymphocytes Modulates B Cell Antigen Receptor-induced Activation of Akt but Has No Effect on MAPK Activation. J. Biol. Chem.
278: 41756-41767
[Abstract]
[Full Text]
-
Dillon, T. J., Karpitski, V., Wetzel, S. A., Parker, D. C., Shaw, A. S., Stork, P. J. S.
(2003). Ectopic B-Raf Expression Enhances Extracellular Signal-regulated Kinase (ERK) Signaling in T Cells and Prevents Antigen-presenting Cell-induced Anergy. J. Biol. Chem.
278: 35940-35949
[Abstract]
[Full Text]
-
Dumont, J. E., Dremier, S., Pirson, I., Maenhaut, C.
(2002). Cross signaling, cell specificity, and physiology. Am. J. Physiol. Cell Physiol.
283: C2-C28
[Abstract]
[Full Text]
-
Johnson, S. A., Rozzo, S. J., Cambier, J. C.
(2002). Aging-Dependent Exclusion of Antigen-Inexperienced Cells from the Peripheral B Cell Repertoire. J. Immunol.
168: 5014-5023
[Abstract]
[Full Text]